Collaborators of Kereos, a biotechnology company developing targeted imaging agents and therapeutics to improve the detection and treatment of cancer and cardiovascular disease, presented preclinical data on two therapeutic candidates at the recent American Heart Association Scientific Sessions.

The collaborators, working out of the Washington University School of Medicine discussed these agents that are the first cardiovascular-targeted therapeutics in Kereos' pipeline of ligand-targeted emulsions, and represent two of the first applications of nanotechnology to treating cardiovascular disease.